March **MIMS** Monthly Medicine Update

NEW PRODUCTS

Madeline **(desogestrel, ethinyloestradiol)** is a combined oral contraceptive. It is contraindicated in the following conditions. Severe hepatic disease (with abnormal LFTs), hepatic tumour, venous (e.g. DVT, PE) or arterial thrombosis (e.g. MI, CVA), prodromal condition (e.g. TIA, angina) (or history); thrombosis predisposition (e.g. activated protein C resistance, hyperhomocysteinaemia, antiphospholipid antibodies, antithrombin III, protein C or S deficiency); severe, multiple risk factors for venous, arterial thrombosis; diabetes with vascular involvement; history of migraine with focal neurological symptoms; pancreatitis (or history if associated with severe hypertriglyceridaemia); undiagnosed vaginal bleeding; known or suspected sex steroid influenced malignancy; and in pregnancy including suspected pregnancy. Madeline is available as a blister pack of 28's containing 21 active tablets (desogestrel 150 microgram, ethinyloestradiol 30 microgram) and 7 placebo tablets.

Optive Advanced **(carmellose sodium, glycerin, polysorbate 80)** is a lubricant eye drop. It is indicated for the temporary relief of burning, irritation and discomfort due to dry eyes or exposure to wind or sun. It may also be used as a protectant against further irritation. Optive Advanced is available as a 15 mL bottle.

Tivicay **(dolutegravir (as dolutegravir sodium))** is an integrase inhibitor active against human immunodeficiency virus (HIV). Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral deoxyribonucleic acid (DNA) integration which is essential for the HIV replication cycle. Tivicay is indicated for the treatment of HIV infection in combination with other antiretroviral agents in adults and children over 12 years of age and weighing 40 kg or more. It is contraindicated in combination with dofetilide. Tivicay is available as 50 mg tablets in bottles of 30's.

NEW INDICATIONS

Neupro **(rotigotine)** is now indicated for the symptomatic treatment of moderate to severe idiopathic restless legs syndrome in adults.

SAFETY RELATED CHANGES

Liver function tests including ALT and total bilirubin should now be monitored every 2 weeks during the first 2 months of treatment with Xalkori **(crizotinib)**, then once a month and as clinically indicated, with more frequent repeat testing for grades 2, 3 or 4 elevations.

Xgeva **(denosumab (rch))** is now contraindicated in severe untreated hypocalcaemia.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.